Feature tracking CMR reveals abnormal strain in preclinical arrhythmogenic right ventricular dysplasia/ cardiomyopathy: a multisoftware feasibility and clinical implementation study

Table 3 Right ventricular regional (segmental) strain values stratified by diagnostic group^d

	Overt ARVD/C (N = 39)	Preclinical ARVD/C (N = 40)	Controls (N = 31)	P-Value^c
Subtricuspid Region
MEDIS	−-28.4 ± 14.8^a	−31.6 ± 10.4^a	−38.1 ± 8.1	0.007
TOMTEC	−24.7 ± 18.3^a	−32.4 ± 12.6	−34.3 ± 11.4	0.045
MTT	−24.4 ± 10.8^ab	−33.4 ± 10.9	−36.9 ± 10.5	<0.001
CIRCLE	−23.0 ± 8.4^a	−26.2 ± 6.3	−27.0 ± 5.0	0.067
Anterior Wall Region
MEDIS	−20.6 ± 10.5^ab	−28.6 ± 10.3	−29.0 ± 11.1	0.001
TOMTEC	−17.5 ± 11.9	−19.7 ± 11.1	−22.6 ± 12.5	0.248
MTT	−17.7 ± 6.4 ^ab	−23.0 ± 6.1	−22.8 ± 6.3	0.001
CIRCLE	−22.8 ± 6.2	−24.2 ± 5.0	−25.3 ± 3.4	0.168
Apical Region
MEDIS	−22.8 ± 10.0^b	−27.8 ± 8.7	−25.1 ± 9.6	0.072
TOMTEC	−12.7 ± 10.7	−14.7 ± 10.4	−13.1 ± 8.6	0.674
MTT	−18.6 ± 8.8^ab	−23.3 ± 7.8	−25.5 ± 9.6	0.019
CIRCLE	−18.3 ± 5.4	−19.9 ± 5.1	−19.5 ± 5.6	0.521

^a Statistical significant difference compared to control subjects; ^b Statistical significant difference compared to preclinical subjects; ^c Trend between overt ARVD/C patients, preclinical ARVD/C and control subjects (OneWay ANOVA). Abbreviations: ARVD/C = Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy; MTT = Multimodality Tissue Tracking; N = number of subjects
^dSegments included based on adequate tracking quality: 365/438, 429/468, and 328/360 segments in overt ARVD/C, preclinical ARVD/C and control subjects respectively

ISSN: 1532-429X